RedHill Biopharma Ltd. (RDHL) RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
RedHill Biopharma Ltd. NASDAQ:RDHL Healthcare · Drug Manufacturers - Specialty & Generic
Mkt Cap $3.45M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 2
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
RedHill's partner, the University of Oklahoma, received a five-year, $2.9 million grant from the National Cancer Institute to run clinical trials of RedHill's opaganib combined with CAR T-cell therapy in ultra-high-risk multiple myeloma.
The funding covers a Phase 1b safety and dosing trial of up to 18 patients followed by a Phase 2 study of up to 21 additional patients seeking preliminary evidence of effectiveness, with RedHill expected to supply opaganib at no cost to itself.
The grant is non-dilutive third-party validation of opaganib's oncology potential, but it is modest in scale, run by a third party, and unlikely to have near-term financial impact for RedHill.
• 13d ago AI analysis › Press Release ⚠ 2
Small Caps Test Their 200-Day Line as Yields Grind Higher and Earnings Season Stirs
Conagra Brands reported Q1 fiscal 2027 net sales down 1.4% to $2.6 billion, with organic net sales down 1.1%, per a market-commentary summary of its release.
Adjusted EPS rose 5.1% to $0.41 and management reaffirmed fiscal 2027 guidance of a 10.0%-10.5% adjusted operating margin and $1.40-$1.50 adjusted EPS.
The item itself is third-party market commentary from Stock Preachers/USA Newsroom, not a company disclosure; Conagra also cited dollar-share gains in frozen vegetables, pudding and chili.
• 1mo ago AI analysis › Press Release ⚠ 5
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
RedHill reported H1 2026 results showing no revenue from continuing operations versus $0.3 million a year earlier, with the net loss widening to $6.1 million from $4.1 million.
The company executed a strategic portfolio reset: it sold its 70% Talicia stake to Apotex for $18 million upfront (plus up to $35 million in milestones) and paid Ferring $12 million upfront for exclusive rights to Rebyota and Clenpiq, two FDA-approved GI drugs that generated roughly $37.5 million in combined 2025 net sales.
The balance sheet is fragile: cash was just $5.3 million at June 30, total liabilities of $27.4 million now exceed total assets of $26.3 million, and equity has turned negative, while the release explicitly flags risk around regaining Nasdaq minimum bid price compliance.
On the pipeline, opaganib received FDA rare pediatric disease designation for neuroblastoma with potential Priority Review Voucher upside, and RHB-204 remains Phase 2-ready for Crohn's disease.
• 1mo ago AI analysis › Press Release ● Major ⚠ 2
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
RedHill acquired exclusive commercialization rights to Ferring's Rebyota and Clenpiq for a $12 million upfront payment, fully funded by the recent $18 million divestiture of Talicia.
The two FDA-approved gastrointestinal drugs generated approximately $37.5 million in combined 2025 net sales, providing an immediate commercial revenue stream expected to deliver positive cash flow contributions.
Management views the transaction as a transformational repositioning that creates a larger commercial business under RedHill's control and strengthens its liquidity position.
• 2mo ago AI analysis › Press Release ⚠ 1
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
RedHill Biopharma sold its 70% stake in the Talicia business to Apotex for $18 million in cash upfront, with the potential to earn up to $35 million in sales-based milestones.
The transaction is designed to strengthen RedHill's liquidity and fully fund the commercial expansion of its GI franchise, marking a strategic shift away from Talicia toward broader gastrointestinal and oncology opportunities.
Apotex now holds full ownership of Talicia following its prior acquisition of Cumberland Pharmaceuticals' 30% interest in the product.
• 2mo ago AI analysis › Press Release ⚠ 3
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
RedHill is advancing discussions for its investigational drug opaganib as a potential treatment for the Ebola outbreak, which has now reached 3,221 confirmed cases and 1,407 deaths. The company is coordinating with African health agencies and universities to evaluate the oral drug, which has shown preclinical synergy with Gilead's remdesivir.
Data from a Phase 3 COVID-19 study supports opaganib's use, showing a 70.2% reduction in mortality when used as an add-on to standard care and improving viral RNA clearance times by at least four days. RedHill also noted prior selection of opaganib by U.S. BARDA for Ebola development, boosting confidence in its dual mechanism of action against the virus.
Despite the positive data, the company emphasized that opaganib is an investigational drug not yet approved by any regulatory authority and remains dependent on successful partnership discussions.
• 3mo ago AI analysis › Press Release
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
RedHill Biopharma, a co-commercialization partner of Cumberland Pharmaceuticals for the drug Talicia, closed a private placement raising $6 million in upfront proceeds.
The offering consisted of 8,571,429 ADSs priced at $0.70, with warrants that could generate an additional $13.4 million if exercised in full.
RedHill intends to use the funds to strengthen liquidity and pursue potential acquisitions of commercial-stage assets.
• 4mo ago AI analysis › Press Release
RedHill Biopharma Announces Up To $19.4 Million Private Placement
RedHill Biopharma, a partner of Cumberland Pharmaceuticals, announced a private placement to raise up to $19.4 million, consisting of $6 million in upfront gross proceeds and potential warrant proceeds.
The offering involves the sale of 8,571,429 ADSs at $0.70 per share, accompanied by Series A-1 and A-2 warrants exercisable immediately.
RedHill plans to use the net proceeds for working capital, R&D, and potential strategic product acquisitions, though no definitive acquisition agreements have been signed.
• 4mo ago AI analysis › Press Release
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
RedHill Biopharma (RDHL) announced that the FDA granted rare pediatric disease designation to its investigational drug opaganib for the treatment of neuroblastoma.
This designation, added to existing orphan drug status, provides potential benefits including a Priority Review Voucher, accelerated review times, and seven years of marketing exclusivity if approved.
Cumberland Pharmaceuticals (CPIX) is the U.S. co-commercialization partner for RedHill's approved drug Talicia, linking CPIX to RedHill's broader pipeline developments, though opaganib is not part of the Talicia agreement.
• 4mo ago AI analysis › Press Release ⚠ 2
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
RedHill Biopharma (RDHL) has commenced enforcement proceedings in Korea regarding a final $10.9 million New York Supreme Court judgment against Kukbo Co. Ltd.
The judgment, which includes $8.9 million in principal and $1.95 million in legal fees, is now final with no further appeals permitted. RedHill has previously secured a Korean court attachment to prevent asset disposal by Kukbo.
Cumberland Pharmaceuticals (CPIX) is mentioned in the boilerplate 'About' section as a U.S. co-commercialization partner for RedHill's drug Talicia. The litigation event is specific to RedHill and does not directly impact Cumberland's operations or financials.
• 4mo ago AI analysis › Press Release ⚠ 4
RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak
RedHill Biopharma is actively discussing collaborations to advance its investigational drug opaganib for the treatment of Ebola virus disease (EVD), including potential inclusion in the WHO's SOLIDARITY CORE clinical trial platform.
The company cites existing Phase 3 data from severe COVID-19 trials showing a 70.2% mortality reduction with opaganib as an add-on therapy, alongside preclinical USAMRIID-funded studies demonstrating opaganib's inhibition of EVD in human macrophages and increased survival in animal models.
Opaganib is positioned as a host-directed therapeutic that can be co-administered with direct-acting antivirals like remdesivir, offering a potential dual mechanism of action against filoviruses. The company has provided supply readiness and safety data to government and industry organizations to facilitate rapid clinical exploration.
• 4mo ago AI analysis › Press Release ⚠ 3
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
RedHill Biopharma (RDHL) is actively discussing collaborations to advance its investigational drug opaganib for the current Ebola virus disease outbreak, including with the WHO's SOLIDARITY CORE platform.
The company cites opaganib's 70.2% mortality reduction in severe COVID-19 trials and preclinical data showing inhibition of EVD and synergistic effects with direct-acting antivirals like remdesivir.
Cumberland Pharmaceuticals (CPIX) is mentioned as the U.S. co-commercialization partner for RedHill's approved drug Talicia, linking CPIX to RedHill's broader biopharma operations, though the Ebola news directly concerns RedHill's pipeline.
• 4mo ago AI analysis › Press Release ● Major
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
prnewswire.com • 6mo ago 
